Sõpruse pst, 10615, Tallinn, Estonia +372-55650441

Announcements

Mohammad Gheibi Appointed as CEO of TULTECH

We are excited to announce that Mohammad Gheibi has been appointed as the new Chief Executive Officer (CEO) of Talent Under Liberty in Technology (TULTECH), effective immediately.

With his extensive experience in research and development, coupled with his visionary leadership, Mohammad Gheibi is well-positioned to lead TULTECH into its next phase of growth and innovation.

Please join us in congratulating Mohammad on his new role and wishing him success in his endeavours as CEO of TULTECH.

New blog posts

Completion of Workshop on Water Recling Simulation and Modelling: Unlocking the Future of Water Management
Completion of Workshop on Water Recling Simulation and Modelling: Unlocking the Future of Water Management

19 March, 2024 by Charlotte Lee

We are thrilled to announce the successful...

IJITIS Journal Meeting and SWOT Analysis at TULTECH
IJITIS Journal Meeting and SWOT Analysis at TULTECH

15 January, 2024 by Charlotte Lee

Greetings, TULTECH community! In our...

A Milestone Meeting for EIL: Shaping the Future of Environmental Industry Letters
A Milestone Meeting for EIL: Shaping the Future of Environmental Industry Letters

15 December, 2023 by Charlotte Lee

Dear TULTECH Community, We are delighted to...

View all blog entries →

Journals

Weather

Drizzle

6°C

Drizzle in Tallinn

Calendar of Events

Closest Events
All events on this day

Researchers create a cancer vaccine that will both treat and prevent brain cancer.

Posted on 6 July, 2023 by benyamin chahkandi

Researchers create a cancer vaccine that will both treat and prevent brain cancer.

Summary: Researchers are using a novel technique to transform cancer cells into effective anti-cancer medicines. Researchers have created a new cell therapy approach to eliminate established tumours and induce long-term immunity, training the immune system to prevent cancer from recurring, in the most recent research from the lab of Khalid Shah, MS, PhD, at Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system. A sophisticated mouse model of the lethal brain disease glioblastoma was used by the research team to test its dual-action, cancer-killing vaccination, with encouraging findings. Results are released in the journal Science Translational Medicine.


"Our team has pursued a simple idea: to take cancer cells and transform them into cancer killers and vaccines," explained corresponding author Khalid Shah, MS, PhD, director of the Centre for Stem Cell and Translational Immunotherapy (CSTI), vice chair of research in the Department of Neurosurgery at the Brigham, and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). We are repurposing cancer cells through gene engineering to create a treatment that kills tumour cells and activates the immune system to eliminate initial tumours and prevent cancer.

Many labs are actively researching cancer vaccinations, but Shah and his colleagues' strategy is unique. The team repurposes living tumour cells since they have an uncommon property, as opposed to employing inactivated tumour cells. Living tumour cells will travel long distances throughout the brain to reunite with their partner tumour cells, much like homing pigeons returning to their nest. Shah's team generated living tumour cells using the gene editing technique CRISPR-Cas9 and repurposed them to release a tumour cell killing agent in order to take advantage of this special trait. Additionally, in order to prime the immune system for a sustained anti-tumor response, the altered tumour cells were created to express characteristics that would make them simple for the immune system to recognise, tag, and recall.

In order to imitate the human immunological microenvironment, the team tested its repurposed CRISPR-enhanced and reverse-engineered therapeutic tumour cells (ThTC) in a variety of mouse strains, including one that had bone marrow, liver, and thymus cells from humans. In addition, the cancer cell has a two-layered safety switch that, when activated, can eliminate ThTCs if necessary. These models demonstrated the safety, applicability, and efficacy of this dual-action cell therapy, providing a path towards treatment. Shah's team purposefully selected this model and used human cells to facilitate the translation of their findings for patient settings, even if more research and development are required.


Even though the work we conduct at the Centre is quite complex, we never lose sight of the patient, according to Shah. Our objective is to adopt a novel but implementable strategy in order to create a therapeutic, cancer-killing vaccine that will ultimately have a long-lasting effect on medicine. Shah and colleagues point out that this therapeutic approach can be used to treat a wider variety of solid tumours and that more research into its potential uses is necessary.

Disclosures: Shah is a shareholder in and a director of AMASA Therapeutics, a business that is working to develop cancer treatments using stem cells.


source: www.sciencedaily.com/releases/2023/01/230104154302.htm


Today In History

Here are some interesting facts ih history happened on 29 March.

  1. Vera Cruz - Mexico falls to Americans
  2. Albert Hall opens in London
  3. Coca-Cola created (with cocaine)
  4. Jack Benny debuts on radio
  5. Yanks & Red Sox tie at 2-2 in 17 - spring training game
  6. 23rd Amendment ratified - Wash DC can vote for pres.
  7. 1st Lt William L Calley Jr found guilty in My-Lai massacre
  8. US troops leave Vietnam - 9 yrs after Tonkin Resolution
  9. Mariner 10's 1st fly-by of Mercury - returns photos
  10. Only 2nd time Islanders beat Rangers